Covered recipient · General Payments record
LAUREN A BYERS
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$149,383.58
- Reported across 153 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $19,916.50 | 6 |
| Travel and Lodging | $1,418.43 | 5 |
| Food and Beverage | $630.63 | 14 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $16,692.62 | 14 |
| Amgen Inc. | $2,744.00 | 1 |
| Acerta Pharma LLC | $1,669.25 | 7 |
| Daiichi Sankyo Inc. | $522.19 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $337.50 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (25)
Sorted by paying entity, then date · as published by CMS
Program year 2024 201820192020202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $45.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103400217 | CMS |
| ABBVIE INC. | $55.00 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103400219 | CMS |
| ABBVIE INC. | $417.94 | 06/26/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104179390 | CMS |
| ABBVIE INC. | $10.75 | 06/26/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104179392 | CMS |
| ABBVIE INC. | $4,196.25 | 08/13/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103132529 | CMS |
| ABBVIE INC. | $64.00 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103400221 | CMS |
| ABBVIE INC. | $233.63 | 10/24/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104179394 | CMS |
| ABBVIE INC. | $14.99 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103400223 | CMS |
| ABBVIE INC. | $34.98 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103400225 | CMS |
| ABBVIE INC. | $14.99 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103400227 | CMS |
| ABBVIE INC. | $48.98 | 10/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103400229 | CMS |
| ABBVIE INC. | $483.50 | 10/25/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104179396 | CMS |
| ABBVIE INC. | $10,800.00 | 11/07/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1103132531 | CMS |
| ABBVIE INC. | $272.61 | 11/11/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1104179398 | CMS |
| Amgen Inc. | $2,744.00 | 09/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1117518356 | CMS |
| AstraZeneca Pharmaceuticals LP | $80.18 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110537295 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.17 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110538473 | CMS |
| AstraZeneca Pharmaceuticals LP | $45.26 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110539937 | CMS |
| AstraZeneca Pharmaceuticals LP | $52.39 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110540201 | CMS |
| AstraZeneca Pharmaceuticals LP | $49.25 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110543019 | CMS |
| AstraZeneca Pharmaceuticals LP | $50.00 | 09/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1110553232 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,370.00 | 10/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1110553986 | CMS |
| Daiichi Sankyo Inc. | $53.44 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089405028 | CMS |
| Daiichi Sankyo Inc. | $468.75 | 09/25/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1089405026 | CMS |
| Novartis Pharmaceuticals Corporation | $337.50 | 03/12/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1086780869 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.